The economics of cardiovascular disease in the United States

Crit Care Clin. 2012 Jan;28(1):77-88, vi. doi: 10.1016/j.ccc.2011.10.007.

Abstract

Cardiovascular disease is the leading cause of death in the United States,and thus its clinical and economic implications are enormous. In an increasingly cost-conscious economic environment, it is important to understand not only the effectiveness of treatments and technologies but also their cost-effectiveness. The authors review and summarize the evidence on cost-effectiveness of surgical versus medical treatments. This evidence should prove useful at the patient bedside as well as assist policymakers and third party payers in deciding what treatments to cover.

Publication types

  • Review

MeSH terms

  • Cardiovascular Diseases / economics*
  • Cardiovascular Diseases / epidemiology
  • Cardiovascular Diseases / therapy
  • Cardiovascular Surgical Procedures / economics*
  • Cost-Benefit Analysis
  • Health Care Costs
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / economics*
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • United States / epidemiology

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors